Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0TCKFR
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
EP4470568A1 ADC-7
|
|||||
| Synonyms |
EP4470568A1 ADC-7
Click to Show/Hide
|
|||||
| Organization |
Shanghai Mabgen Biotech Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
6
|
|||||
| Structure |
|
|||||
| Antibody Name |
hAb015-10
|
Antibody Info | ||||
| Antigen Name |
B-cell antigen receptor complex-associated protein beta chain (CD79B)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Vedotin
|
|||||
ADC-specific functional property(2027 Update)
Binding Affinity
| Dissocation Constant (Kd) | Binding Target | Description | Reference |
|---|---|---|---|
| 0.53 nM |
humn CD79b
|
The binding kinetics of the antibody-drug conjugate 1 and the antibody-drug conjugate 2 prepared in Example1 and the 900698 naked antibody with a human CD73 protein and a monkey CD73 protein. The human CD73 protein was diluted with the assay buffer to a series of concentrations of 50 nM, 25 nM,12.5 nM, 6.25 nM, 3.12 nM,and 1.57 nM,serving as analytes, and the assay buffer was used as a 0 concentration control. At a flow rate of 30 uL/min, association was conducted for 120 s, and dissociation was conducted for 600s. Glycine (10mM,pH1.5 was used for regeneration at a flow rate of 50 uL/min for 60s in a multi-cycle kinetic assay. A 1:1 binding model was used, and the Fit Local mode was selected to determine the association rate constant (ka), dissociation rate constant (kd), and equilibrium dissociation constant (KD).
Click to Show/Hide
|
[1]
|
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Tumor Growth lnhibition value (TGl) |
91
|
%
|
Undisclosed | Undisclosed |
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | 91% | High CD79b expression (CD79b +++) | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 2 ng/mL | High CD79b expression (CD79b +++) | ||
| Method Description |
A certain number of DoHH2 cells in the logarithmic growth phase were seeded into a 96-well culture plate, and drugs at different concentrations were added to the culture plate for reaction for 72 h. After the reaction was completed, an MTT working solution was added for reaction for 6h, then blue-purple crystalline formazan was dissolved with atriplex solution.
Click to Show/Hide
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma germinal center B-cell type | DoHH2 cells | CVCL_1179 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 53.4 ng/mL | High CD79b expression (CD79b +++) | ||
| Method Description |
A certain number of DoHH2 cells in the logarithmic growth phase were seeded into a 96-well culture plate, and drugs at different concentrations were added to the culture plate for reaction for 72 h. After the reaction was completed, an MTT working solution was added for reaction for 6h, then blue-purple crystalline formazan was dissolved with atriplex solution.
Click to Show/Hide
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma germinal center B-cell type | DoHH2 cells | CVCL_1179 | ||
References